Abliva AB (publ) (STO:ABLI)

Market Cap	725.35M
Revenue (ttm)	137.00K
Net Income (ttm)	-88.71M
Shares Out	1.61B
EPS (ttm)	-0.07
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11,504,363
Average Volume	4,384,138
Open	0.450
Previous Close	0.450
Day's Range	0.449 - 0.451
52-Week Range	0.114 - 0.455
Beta	0.94
RSI	85.53
Earnings Date	Feb 21, 2025

About Abliva AB

Abliva AB (publ) discovers and develops medicines for the treatment of mitochondrial disease in Sweden. The company is developing KL1333 that is in Phase 2 clinical trial to treat chronic fatigue and myopathy in genetically confirmed adult patients with primary mitochondrial disease; and NV354, which has completed preclinical development for the treatment of mitochondrial disease with neurologic complications. It has a licensing and collaboration agreement with Owl Therapeutics for NeuroSTAT for the treatment of traumatic brain injury; and Yung...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 8
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: ABLI

Financial Performance

In 2023, Abliva AB's revenue was 137,000, an increase of 341.94% compared to the previous year's 31,000. Losses were -95.51 million, 12.0% more than in 2022.